The effectiveness of treatment in patients with destructive pulmonary tuberculosis depending on the mode of administration of antimtuberculosis drugs
No Thumbnail Available
Files
Date
2017-01-14
Authors
Kuzhko, Mykhailo
Gumeniuk, Mykola
Butov, Dmytro
Tlustova, Tetiana
Denysov, Oleksii
Sprynsian, Tetiana
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background and objective. The aim of research was to determine the effectiveness of chemotherapy using
intravenous (i/v) antimtuberculosis drugs compared with their oral administration during the intensive phase (IP) of treatment in patients with destructive pulmonary tuberculosis (TB).
Methods. 130 TB patients were randomized into 2 groups: Main (n=65) who received isoniazid, ethambutol and sodium rifamycin i/v + pyrazinamide per os and control (n=65) who received all the drugs (isoniazid, rifampicin, ethambutol, pyrazinamide) orally.
Results. After 2 weeks of treatment symptoms of intoxication disappeared in 90.7% of patients of the main group (MG) and 75.0% patients in the control group (CG), p<0.05. The mean duration of symptoms of intoxication in patients MG was 9,6±0,7 days, in CG -13.4±1.2 days. After completing IP sputum conversion was found in all the patients MG and 43 (95.7%) patients CG. The average time of sputum conversion in MG was 1.6±0.1 months and 1.8±0.1 months in CG, p>0.05. In patients with destructive pulmonary TB time to sputum conversion was 1.7±0.1 months in MG and 2.1±0.1 months in CG, p<0.05. The average time of cavities healing in MG was 2.9±0.2 months and 3.7±0.3 months in the CG, p<0.05.
Conclusions. In patients with destructive pulmonary TB use of isoniazid, ethambutol and sodium rifamycin i/v in the intensive phase of chemotherapy resulted in a significant reduction in terms of the disappearance of symptoms of intoxication and sputum conversion.
Funding acknowledgement: the study was supported by the National Academy of Medical Sciences of Ukraine.
Description
Keywords
antimtuberculosis drugs, tuberculosis
Citation
The effectiveness of treatment in patients with destructive pulmonary tuberculosis depending on the mode of administration of antimtuberculosis drugs / M. Kuzhko, M. Gumenyuk, D. Butov, T. Tlustova, O. Avramchuk, O. Denysov, T. Sprynsian // New Developments in Our Basic Understanding of Tuberculosis : Keystone Symposia on Molecular and Cellular Biology, Vancouver, Canada, 14–18 January 2017. – Vancouver, 2017. – P. 111.